Form 4: Director Lisa Johnson-Pratt Receives ASMB Stock Options

Assembly Biosciences director Lisa Johnson-Pratt was granted 8,000 stock options as part of a standard equity compensation plan.

Summary

• Director Lisa Johnson-Pratt received a grant of 8,000 stock options for Assembly Biosciences, Inc. (ASMB) common stock.
• The options have an exercise price of $24.11 per share.
• The grant date for the transaction was June 4, 2026.
• The options are scheduled to vest on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Market volatility could impact the value of the options, potentially affecting director retention or incentive alignment.

Future Outlook

The options vest in one year, contingent upon continuous service, indicating a standard retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term clinical and commercial development.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in small-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

ASMB, Assembly Biosciences, Form 4, Insider Trading, Stock Options, Director Compensation